author-photo

Edwin P. Rock

University of Pennsylvania

22

Papers

1310

Citations

Citation Trend

Filter By

Papers (22) Sort By

JournalConferenceOthers

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial.

2021 JAMA Oncology
Show All
- Source
- Cite
- Save
Citations (33)
Abstract PS9-11: Health-related quality of life for margetuximab + chemotherapy vs. trastuzumab + chemotherapy in the phase 3 SOPHIA trial of patients with pretreated HER2+ metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS10-12: Integrated safety summary of single agent and combination margetuximab in phase 1, 2, and 3 studies of HER2-positive advanced cancers and metastatic breast cancer (MBC)

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract PS10-24: Infusion related reactions in the phase 3 SOPHIA trial of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with pretreated HER2+ metastatic breast cancer

2021 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract P1-18-04: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: Infusion time substudy results

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract GS1-02: Phase 3 SOPHIA study of margetuximab + chemotherapy vs trastuzumab + chemotherapy in patients with HER2+ metastatic breast cancer after prior anti-HER2 therapies: second interim overall survival analysis

2020 Cancer Research
Show All
- Source
- Cite
- Save
Citations (19)
SOPHIA analysis by chemotherapy (Ctx) choice: A phase III (P3) study of margetuximab (M) + Ctx versus trastuzumab (T) + Ctx in patients (pts) with pretreated HER2+ metastatic (met) breast cancer (MBC).

2020 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (2)
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (53)
High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (6)
Dosing algorithm revisit for busulfan following IV infusion.

2015 Cancer Chemotherapy and Pharmacology
Show All
- Source
- Cite
- Save
Citations (4)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号